Products - Colorectal cancer | Topic | NICE

Showing 23 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter
Guidance programme: Diagnostics guidanceRemove ‘Guidance programme: Diagnostics guidance’ filter
Guidance programme: Medical technologies guidanceRemove ‘Guidance programme: Medical technologies guidance’ filter
Status: PublishedRemove ‘Status: Published’ filter

Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (TA1008)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 September 2024
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (TA914)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 September 2023
Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care (DG56)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
24 August 2023
Regorafenib for previously treated metastatic colorectal cancer (TA866)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 February 2023
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA716)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 July 2021
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 June 2021
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 January 2021
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 May 2020
Endocuff Vision for assisting visualisation during colonoscopy (MTG45)
Product type:
Guidance
Programme:
Medical technologies guidance
Published:
7 June 2019
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
25 September 2017
Published:
29 March 2017
Virtual chromoendoscopy to assess colorectal polyps during colonoscopy (DG28)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
10 May 2017
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TA240)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
29 March 2017
Published:
14 December 2011
Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
22 February 2017
Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 August 2016
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 February 2015
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
10 December 2014
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 March 2014
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 January 2012
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 January 2012
Published:
24 January 2007
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 December 2010
Laparoscopic surgery for colorectal cancer (TA105)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 August 2006
Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer (TA100)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 April 2006
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 May 2003